Ocriplasmin is a useful clinical tool; careful case selection will improve treatment results.
This editorial discusses the significance of the first reported case series of real-world use of ocriplasmin for treating symptomatic vitreomacular adhesion and addresses the importance of case selection in improving treatment results.